Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06576401
PHASE1

A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

In this study, a single dose of \[14C\] radiolabelled HDM1002 will be administered orally. The main purpose of this study is to find out how much of HDM1002 and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral \[14C\] HDM002.

Official title: A Phase1 Study to Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

Key Details

Gender

MALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2024-08-27

Completion Date

2024-12

Last Updated

2024-09-04

Healthy Volunteers

Yes

Interventions

DRUG

[14C] HDM1002

Administered orally

Locations (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China